62nd ASH Annual Meeting and Exposition: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster III

Oral and Poster Abstracts
Poster

antibodies, apheresis, apoptosis, Biological, Follicular Lymphoma, Leukemia, cell division, CLL, Diseases, Lymphoma (any), Non-Biological, Combinations, Mantle Cell Lymphoma, Therapies, checkpoint inhibitors, chemotherapy, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Biological Processes, enzyme inhibitors, white blood cells, immune cells, Immune Disorders, T-Cell Lymphoma, Technology and Procedures, Cell Lineage, immunotherapy, Xenograft models, Lymphoid Malignancies, Study Population, Clinically relevant, NK cells, flow cytometry, TKI, molecular testing, multi-systemic interactions, pathways

3007

Mechanisms of Therapeutic Response to Tipifarnib in a Mouse Model of Angioimmunoblastic T-Cell Lymphoma

Jose Rodriguez Cortes¹^*, Anisha Cooke²^*, Aidan Quinn³^*, Bobby B Shih⁴^*, Ioan Filip, PhD⁵^*, Juan Angel Patino, PhD⁶^*, Raul Rabadan, PhD^5,7^*, Adolfo Ferrando, M.D., PhD^2,8,9^* and Teresa Palomero, PhD^2,10

¹Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY
²Institute for Cancer Genetics, Columbia University, New York, NY
³Columbia University, New York, NY
⁴Columbia University Medical Center, New York, NY
⁵Department of Systems Biology, Columbia University, New York, NY
⁶Department of Systems Biology, Columbia University, New York
⁷Department of Biomedical Informatics, Columbia University, New York
⁸Department of Pediatrics, Columbia University Medical Center, New York, NY
⁹Department of Pathology, Columbia University Medical Center, New York, NY
¹⁰Department of Pathology and Cell Biology, Inst. for Cancer Genetics Columbia University, New York, NY

3008

Blockade of the CD47/SIRPα Checkpoint Potentiates the Anti-Tumor Efficacy of Tafasitamab

Doris Mangelberger^*, Christian Augsberger^*, Karin Landgraf^*, Christina Heitmüller^* and Stefan Steidl^*

MorphoSys AG, Planegg, Germany

3009

KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created By a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity By Adding T Cell-Mediated Cytotoxicity Activity to the Existing Mechanisms of Rituximab

Christian Vidal, PhD¹^*, Michael Cukan, PhD¹^*, Ada Vaill, MS¹^*, Anna Bunin, PhD¹^*, Ann Marie Rossi, MS¹^*, Lawrence Iben, MA¹^*, David Trinh, BS¹^*, Katy McGrath, BS¹^*, Tanya Berbasova, PhD¹^*, Rizwan Romee, MD², Enrique Alvarez, DVM¹^*, Luca Rastelli, PhD¹^* and Matthew Welsch, PhD¹^*

¹Kleo Pharmaceuticals, New Haven, CT
²Dana-Farber Cancer Institute, Boston, MA

3010

Overcoming CAR T Resistance with Non-Covalent BTK Inhibitor Loxo-305 in Mantle Cell Lymphoma

Yang Liu, PhD¹^*, Vivian Changying Jiang, PhD¹, Joseph McIntosh, BS¹^*, Alexa A Jordan, BS¹^*, Yijing Li, MS¹^* and Michael Wang, MD^1,2

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

3011

Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity

Eugenio Gaudio, PhD¹^*, Chiara Tarantelli, PhD¹^*, Luciano Cascione, PhD^1,2^*, Filippo Spriano¹^*, Gaetanina Golino, PhD^1,3^*, Lorenzo Scalise⁴^*, Emanuele Zucca, MD^1,5, Anastasios Stathis, MD⁶^*, Patrick H Van Berkel, PhD⁷^*, Francesca Zammarchi, PhD⁸^* and Francesco Bertoni, MD^1,5

¹Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
²Swiss Institute of Bioinformatics, Lausanne, Switzerland
³Magna Graecia University, Catanzaro, Italy
⁴Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, CHE
⁵Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
⁶Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, Switzerland
⁷ADC Therapeutics (UK) Limited, London, United Kingdom
⁸ADC Therapeutics Limited, London, United Kingdom

3012

Obinutuzumab-Retreatment in Combination with Bendamustine Is Effective for Obinutuzumab Resistant Models in Vitro and In Vivo

Yoriko Yamashita-Kashima, PhD^*, Natsumi Kawasaki, PhD^*, Keigo Yorozu, DVM, PhD^*, Shigeki Yoshiura, PhD^*, Takaaki Fujimura, MS^*, Mitsue Kurasawa, MS^*, Naoki Harada, PhD^* and Yasushi Yoshimura, MS^*

Chugai Pharmaceutical Co., Ltd., KAMAKURA, Japan

3013

Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations

Jennifer Kimberly Lue, MD¹, John S Manavalan, MD²^*, Christine Klaus, BS³^*, Rahul Kanik, PhD³^*, Andre M. Grilo, PhD⁴^*, Alice McDonald, PhD³^*, Jared Gollob, PhD, MD³^*, Duncan Walker, PhD⁵, Owen A. O'Connor, MD, PhD⁶ and Nello Mainolfi, PhD³^*

¹Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY
²Program for T-Cell Lymphoma, Division of Hematology and Oncology, University of Virginia, Charlottesville, VA
³Kymera Therapeutics, Watertown, MA
⁴Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY
⁵Kymera Therapeutics, Cambridge, MA
⁶Division of Hematology and Oncology; Program for T-Cell Lymphoma Research, University of Virginia, Charlottesville, VA

3014

Combination of Bortezomib and Venetoclax Induces Synergistic Killing of Epstein-Barr Virus-Driven Lymphoproliferative Diseases By Targeting the Pro-Survival Function of Latent Membrane Protein-1 and Epstein-Barr Nuclear Antigen-3C

Alan Kwok Shing Chiang, MBChB, PhD¹, Kam Pui Tam, BSc¹^* and Rex Kwok Him Au-Yeung, MBBS²^*

¹Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, DC, China
²Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

3015

Anti-CD20-Mediated B Cell Depletion Is Associated with Reduced Osteoclastogenic Signals and Bone Mass Preservation: Clinical Observation in Patients with Follicular Lymphoma Supplemented By Animal Studies in a Murine Model

Albert Kolomansky, MD^1,2^*, Irit Kay, MD²^*, Nathalie Ben-Califa, PhD¹^*, Anton Gorodov, BSc¹^*, Zamzam Awida, BSc¹^*, Ofer Sadovnic, MD³^*, Maria Ibrahim, BSc¹^*, Tamar Liron, PhD⁴^*, Sahar Hiram-Bab, PhD⁴^*, Howard S. Oster, MD, PhD², Nadav Sarid, MD⁵^*, Chava Perry, MD, PhD⁵^*, Yankel Gabet, DMD, PhD⁴^*, Moshe Mittelman, MD^2,5 and Drorit Neumann, PhD¹

¹Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
²Department of Internal Medicine A, Tel Aviv Sourasky Medical Center/Sackler Faculty of Medicine, Tel Aviv, Israel
³Radiology department, Tel Aviv Sourasky Medical Center/Sackler Faculty of Medicine, Tel Aviv, Israel
⁴Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
⁵Department of Hematology, Tel Aviv Sourasky Medical Center/Sackler Faculty of Medicine, Tel Aviv, Israel

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH